Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Oñate, Guadalupe
• dc.contributor.author Garcia-Avila, Sara
• dc.contributor.author Sierra, Jorge
• dc.date.accessioned 2025-10-21T13:39:02Z
• dc.date.available 2025-10-21T13:39:02Z
• dc.date.issued 2025
• dc.date.updated 2025-10-21T13:39:02Z
• dc.description.abstract Given the heterogeneity of acute myeloid leukemia patients, it is necessary to identify patients considered fit for intensive therapy but who will perform poorly, and in whom alternative approaches deserve investigation. We analyzed 1034 fit adults ≤70 years intensively treated between 2012 and 2022 in the CETLAM group. Young adults ( ≤ 60 years) presented higher remission rates and improved survival than older adults above that age (CR 79% vs. 73%; p = 0.03 and 4-yr OS 53% vs. 33%; p < 0.001). Remission and survival outcomes varied among different genetic subsets. An especially adverse genetic group included complex, monosomal karyotype, TP53 alterations (deleted/mutated), and MECOMr. Transplant feasibility in this very adverse risk group was low, and OS and EFS at 4 years were 14% and 12%, in contrast to 70% and 57% in the favorable group and 38% and 32% in all other patients. We integrated clinical and genetic data into the Intensive Chemotherapy Score for AML (ICSA) with 6-risk categories with significantly different remission rates and OS, validated in another cohort of 581 AML patients from a previous CETLAM protocol. In summary, we identified groups of fit patients that benefit differently from an intensive approach which may be helpful in future treatment decisions.
• dc.format.mimetype application/pdf
• dc.identifier.citation Oñate G, Garrido A, Arnan M, et al. Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group. Blood Cancer J. 2025 Jan 11;15(1):4. DOI: 10.1038/s41408-024-01205-5
• dc.identifier.doi http://dx.doi.org/10.1038/s41408-024-01205-5
• dc.identifier.issn 2044-5385
• dc.identifier.uri http://hdl.handle.net/10230/71611
• dc.language.iso eng
• dc.publisher Nature Research
• dc.relation.ispartof Blood Cancer Journal. 2025;15(1):4
• dc.rights © The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
• dc.subject.keyword Acute myeloid leukaemia
• dc.subject.keyword Chemotherapy
• dc.title Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion